July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Conjunctival Injection Reduction in Patients with Atopic Keratoconjunctivitis After Administration of Enteric-Coated Lactoferrin
Author Affiliations & Notes
  • Hiroshi Fujishima
    Ophthalmology, Tsurumi Univ School of Dental Med, Yokohama, KANAGAWA, Japan
  • Kazumi Fukagawa
    Ophthalmology, Ryogoku eye clinic, Tokyo, Japan
  • Hiroyuki Yazu
    Ophthalmology, Keio University School of medicine, Tokyo, Japan
  • Eisuke Shimizu
    Ophthalmology, Keio University School of medicine, Tokyo, Japan
  • Naoko Okada
    Ophthalmology, Tsurumi Univ School of Dental Med, Yokohama, KANAGAWA, Japan
  • Footnotes
    Commercial Relationships   Hiroshi Fujishima, Alcon Laboratories, Inc (F), Kobayashi Pharmaceutical Co., Ltd (F), Otsuka Pharmaceutical Co., Ltd (F), Santen, Pharmaceutical Co., Ltd (F), Senju Pharmaceutical Co., Ltd (F), White Medical Co., Ltd (F); Kazumi Fukagawa, None; Hiroyuki Yazu, None; Eisuke Shimizu, None; Naoko Okada, None
  • Footnotes
    Support  Alcon Laboratories, Inc., Santen, Pharmaceutical Co., Ltd, and White Medical Co., Ltd
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5565. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hiroshi Fujishima, Kazumi Fukagawa, Hiroyuki Yazu, Eisuke Shimizu, Naoko Okada; Conjunctival Injection Reduction in Patients with Atopic Keratoconjunctivitis After Administration of Enteric-Coated Lactoferrin. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5565.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Lactoferrin (LF), a multifunctional glycoprotein found in mammalian milk, is reported to have immunoregulatory effects. The present study aimed to evaluate whether enteric-coated LF (eLF) can improve conjunctivitis in patients with atopic keratoconjunctivitis (AKC).

Methods : This randomized double-blind placebo-controlled single-centre trial comprised Japanese patients (n = 20; aged 22–60 years) with AKC. Patients were administered eLF (400 mg/d bovine LF) or placebo tablets for 12 weeks. Conjunctival injection examined using slit-lamp photography and graded by three blinded allergy specialist ophthalmologists (worse +1, no change 0, or improved -1). Serum allergic parameters and skin conditions were also assessed.

Results : There was a significant reduction in conjunctival injection in the eLF group (-3.0) compared with the placebo control group (+4.0; Mann-Whitney U-test; p=0.0017), and papillae formation in the palpebral conjunctiva (p=0.01, Wilcoxon rank sum test). There were no adverse effects of eLF treatment regarding serum allergic parameters and patient skin condition.

Conclusions : eLF seems a promising agent for the control of AKC.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×